Implications for ProMIS, PMN310, and the PRECISE-AD Trial (GlobeNewswire) - Dec 1, 2025 - "The newly published analysis is directly aligned with, and supportive of, key elements of the PRECISE-AD design: Biomarker-centric strategy: PRECISE-AD incorporates plasma pTau (including pTau217) as a central biomarker endpoint at 6 and 12 months, consistent with the timing and methodology highlighted in the publication; Early readout with potentially predictive value: By assessing plasma pTau changes as early as 6 months, PRECISE-AD is positioned to generate an early, quantitative signal of disease modification that can be used to model and predict future clinical outcomes....'Importantly, we remain on track to assess blinded 6-month biomarker data, including plasma pTau217, from our PRECISE-AD trial in Q2 2026.'"
P1 data • Trial status • Alzheimer's Disease • Tauopathies And Synucleinopathies
|